This year’s winners of the Lupus Foundation of America‘s Gary S. Gilkeson Career Development Award — designed to support early career scientists working on lupus research — will focus their work on areas key to patients with the autoimmune disease: pregnancy and personalized medicine. Both winners are from…
News
A team of scientists in Austria discovered a small molecule — now called feeblin in a nod to a Nobel laureate— that prevents the activation of immune signaling pathways implicated in systemic lupus erythematosus (SLE). This molecule was found to block the interaction of two key proteins, known as…
Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the accelerated evaluation of upadacitinib as a potential treatment for individuals living with SLE,” Stacie Bell, PhD, Lupus Therapeutics’…
Lupus Therapeutics will partner with Nkarta to advance the development of NKX019, Nkarta’s investigational natural killer (NK) cell therapy, for people with treatment-resistant lupus nephritis, a serious complication of lupus that features kidney damage and dysfunction. The U.S. Food and Drug Administration (FDA) recently cleared the launch…
The U.S. Food and Drug Administration (FDA) has approved Nkarta’s request to launch a clinical trial in the U.S. to test its experimental therapy NKX019 in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The multi-center, dose-escalation study will assess the safety and clinical…
Treatment with an intensified dosing regimen of Saphnelo (anifrolumab) led to greater improvements in kidney function compared with standard dosing or a placebo for people with active lupus nephritis, according to two-year data from the TULIP-LN clinical trial. Lupus nephritis is a common, yet severe manifestation of lupus…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to IMPT-514, a CAR T-cell therapy being developed by Immpact Bio for people with active, treatment-resistant lupus nephritis and systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of lupus characterized by kidney inflammation.
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for autoimmune diseases is tied to serious side effects — among people with moderate to severe lupus. To that end, healthcare professionals are increasingly prescribing biological therapies like Benlysta…
A $1.6 million gift from business executive William J. Wolfe and his family will establish the Wolfe Lupus Research Fund at the University of California (UC) San Diego to advance lupus research and patient care. Wolfe, a longtime lupus community supporter, is a board member of the Lupus…
A personalized vaccine kit designed to prevent COVID-19 infection eased systemic lupus erythematosus (SLE) manifestations in an adolescent girl in Indonesia whose symptoms had not been well-controlled with immunosuppressive therapies, a study showed. Researchers believe that while the therapy was not specifically targeted for SLE, it helped the girl…
Recent Posts
- Galápagos’ oral therapy for lupus fails to meet key trial objective
- What I learned about navigating travel anxiety with lupus
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?